Loading…
3 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Aversi-Rational | Pharma | 17.8% | 55th pct | 110 |
| Aversi-Pharma | Pharma | 11.2% | 43rd pct | 110 |
| Natusana | (unclassified) | — | no FY data | 1208 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 3 peers filed FY2024. Switch to FY2019 (3 of 3).
| Line item | Aversi-Pharma | Aversi-Rational | Natusana |
|---|---|---|---|
| Total Current Assets | 399,099 | 43,672 | — |
| Total Non-Current Assets | 411,105 | 10,490 | — |
| TOTAL ASSETS | 810,204 | 54,162 | — |
| Total Current Liabilities | 224,988 | 26,315 | — |
| Total Non-Current Liabilities | 75,707 | 1,354 | — |
| TOTAL LIABILITIES | 300,695 | 27,668 | — |
| Total Equity | 509,509 | 26,494 | — |
| Balance Check (Assets - L&E) | 0 | 0 | — |
| Total Debt | 83,230 | 0 | — |
| Cash & Equivalents | 32,124 | 131 | — |
| Net Debt | 51,106 | -131 | — |
Not every picked company reports every selected year — FY2024: no filing for Natusana. Those cells are left blank (no filing), not zero.